ALK, ROS1, NTRK, FGFR and RET fusions now define an important subset of non-small cell lung cancers (NSCLC) and other malignancies with FDA-approved targeted inhibitors (1–9). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.